[ Price : $8.95]
FDA requires safety labeling changes about Guillain-Barr syndrome risks for Pfizers Abrysvo (respiratory syncytial virus vaccine) ...[ Price : $8.95]
FDA publishes a draft guidance on developing drugs for optical imaging for three purposes.[ Price : $8.95]
FDA accepts for priority review a Dizal NDA for sunvozertinib, an oral EGFR inhibitor for treating locally advanced or metastatic ...[ Price : $8.95]
FDA posts a draft guidance entitled Considerations for Including Tissue Biopsies in Clinical Trials.[ Price : $8.95]
FDA releases a draft guidance entitled Considerations for the Use of Artificial Intelligence (AI) to Support Regulatory Decision-M...[ Price : $8.95]
Neumora Therapeutics says its Phase 3 KOASTAL-1 Study of navacaprant for treating major depressive disorder missed its primary end...[ Price : $8.95]
CDER approves 50 novel products in 2024, five less than the 55 products approved in 2023 and well above the 10-year rolling annual...[ Price : $8.95]
FDA approves Ionis Spinraza as the first drug approved to treat children and adults with spinal muscular atrophy.